Business Standard

Monday, December 23, 2024 | 03:32 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Divi's Lab, Aurobindo Pharma: Are pharma stocks losing their sheen? Read on

Till Nifty Pharma holds above the 11,180 mark, the bullish bias will prevail, charts suggest.

v
Premium

With a negative crossover of 100-DMA with 50-DMA, Aurobindo Pharma is exhibiting a negative view.

Avdhut Bagkar Mumbai
It seems stock markets have got a new lease of life after two favourable developments - Joe Biden's win in US Presidential elections and drug company Pfizer's announcement that its experimental Covid-19 vaccine was more than 90 per cent effective based on initial trial results.

The benchmark indices logged fresh high levels for the second consecutive session on Tuesday. On Wednesday, too, they rallied in the early deals but slipped later due to profit-booking. Amid this dream rally, sectors that have outperformed this year — such as information technology (IT) and pharmaceutical - fell sharply. For instance, both Nifty IT

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in